-
1
-
-
84933678156
-
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
-
Eggermont AM, Chiarion-Sileni V, Grob -J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071):a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–530.
-
(2015)
Lancet Oncol
, vol.16
, Issue.5
, pp. 522-530
-
-
Eggermont, A.M.1
Chiarion-Sileni, V.2
Grob, J.3
-
2
-
-
84961588720
-
Advances in cancer immunology and cancer immunotherapy
-
Voena C, Chiarle R., Advances in cancer immunology and cancer immunotherapy. Discov Med. 2016;21(114):125–133.
-
(2016)
Discov Med
, vol.21
, Issue.114
, pp. 125-133
-
-
Voena, C.1
Chiarle, R.2
-
3
-
-
84946607195
-
Nivolumab versus everolimus in advanced renal-cell carcinoma
-
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
-
(2015)
N Engl J Med
, vol.373
, Issue.19
, pp. 1803-1813
-
-
Motzer, R.J.1
Escudier, B.2
McDermott, D.F.3
-
4
-
-
84965149585
-
Immune checkpoint inhibitors in lung cancer: past, present and future
-
Seetharamu N, Budman DR, Sullivan KM. Immune checkpoint inhibitors in lung cancer:past, present and future. Future Oncol. 2016;12(9):1151–1163.
-
(2016)
Future Oncol
, vol.12
, Issue.9
, pp. 1151-1163
-
-
Seetharamu, N.1
Budman, D.R.2
Sullivan, K.M.3
-
5
-
-
84959869247
-
Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non- small cell lung cancer (NSCLC): a review on toxicity profile and its management
-
Sgambato A, Casaluce F, Sacco PC, et al. Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non- small cell lung cancer (NSCLC):a review on toxicity profile and its management. Curr Drug Saf. 2016;11(1):62–68.
-
(2016)
Curr Drug Saf
, vol.11
, Issue.1
, pp. 62-68
-
-
Sgambato, A.1
Casaluce, F.2
Sacco, P.C.3
-
6
-
-
84930912300
-
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a ‘new frontier’?
-
Pilotto S, Kinspergher S, Peretti U, et al. Immune checkpoint inhibitors for non-small-cell lung cancer:does that represent a ‘new frontier’?. Anticancer Agents Med Chem. 2015;15(3):307–313.
-
(2015)
Anticancer Agents Med Chem
, vol.15
, Issue.3
, pp. 307-313
-
-
Pilotto, S.1
Kinspergher, S.2
Peretti, U.3
-
7
-
-
84879579673
-
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
-
Intlekofer AM, Thompson CB. At the bench:preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25–39.
-
(2013)
J Leukoc Biol
, vol.94
, Issue.1
, pp. 25-39
-
-
Intlekofer, A.M.1
Thompson, C.B.2
-
8
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
-
(2010)
N Engl J Med
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O’Day, S.J.2
McDermott, D.F.3
-
9
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
-
(2015)
N Engl J Med
, vol.372
, Issue.21
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
-
10
-
-
84936791837
-
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
-
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
-
(2015)
N Engl J Med
, vol.373
, Issue.2
, pp. 123-135
-
-
Brahmer, J.1
Reckamp, K.L.2
Baas, P.3
-
11
-
-
84962038946
-
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
-
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 2016;387(10030):1837–1846.
-
(2016)
The Lancet
-
-
Fehrenbacher, L.1
Spira, A.2
Ballinger, M.3
-
12
-
-
84942236061
-
Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis
-
Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors:a meta-analysis. Future Oncol. 2015;11(17):2471–2484.• This work evaluated the incidence and risk of various cutaneous toxicities among solid tumor patients treated with immune checkpoint inhibitors.
-
(2015)
Future Oncol
, pp. 2484
-
-
Abdel-Rahman, O.1
ElHalawani, H.2
Fouad, M.3
-
13
-
-
84942294585
-
Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
-
Abdel-Rahman O, ElHalawani H, Fouad M. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors:a meta-analysis. Expert Opin Drug Saf. 2015;14(10):1507–1518.• This work summarizes the incidence and risk of elevated transaminases among solid tumor patients treated with immune checkpoint inhibitors.
-
(2015)
Expert Opin Drug Saf
, vol.14
, Issue.10
, pp. 1507-1518
-
-
Abdel-Rahman, O.1
ElHalawani, H.2
Fouad, M.3
-
14
-
-
84961325991
-
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis
-
Abdel-Rahman O, ElHalawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors:a meta-analysis. Future Oncol. 2016;12(3):413–425.• This work summarizes the incidence and risk of endocrine toxicities among solid tumor patients treated with immune checkpoint inhibitors.
-
(2016)
Future Oncol
, pp. 425
-
-
Abdel-Rahman, O.1
ElHalawani, H.2
Fouad, M.3
-
15
-
-
84948171577
-
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
-
Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors:a meta-analysis. Immunotherapy. 2015;7(11):1213–1227.
-
(2015)
Immunotherapy
, vol.7
, Issue.11
, pp. 1213-1227
-
-
Abdel-Rahman, O.1
ElHalawani, H.2
Fouad, M.3
-
16
-
-
84973573023
-
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
-
Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors:a meta-analysis. Ther Adv Respir Dis. 2016;10:183–193.
-
(2016)
Ther Adv Respir Dis
, vol.10
, pp. 183-193
-
-
Abdel-Rahman, O.1
Fouad, M.2
-
17
-
-
84991214698
-
Treatment-related death in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
-
Abdel-Rahman O, Helbling D, Schmidt J, et al. Treatment-related death in cancer patients treated with immune checkpoint inhibitors:a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2016. Doi:10.1016/j.clon.2016.11.007.
-
(2016)
Clin Oncol (R Coll Radiol)
-
-
Abdel-Rahman, O.1
Helbling, D.2
Schmidt, J.3
-
18
-
-
84968911282
-
A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors
-
Abdel-Rahman O, Fouad M. A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. Immunotherapy. 2016;8(5):665–674.
-
(2016)
Immunotherapy
, vol.8
, Issue.5
, pp. 665-674
-
-
Abdel-Rahman, O.1
Fouad, M.2
-
19
-
-
84991214698
-
Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors; a systematic review and meta-analysis
-
Abdel-Rahman O, Helbling D, Schmidt J, et al. Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors; a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2016;28(10):e127–38.
-
(2016)
Clin Oncol (R Coll Radiol)
, vol.28
, Issue.10
, pp. e127-e138
-
-
Abdel-Rahman, O.1
Helbling, D.2
Schmidt, J.3
-
20
-
-
80052307183
-
Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]
-
Higgins JPT, Green S, (editors). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from:www.cochrane-handbook.org.
-
(2011)
The Cochrane Collaboration
-
-
Higgins, J.P.T.1
Green, S.2
-
21
-
-
0022992740
-
Meta-analysis in clinical trials
-
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
-
(1986)
Control Clin Trials
, vol.7
, Issue.3
, pp. 177-188
-
-
DerSimonian, R.1
Laird, N.2
-
23
-
-
84901641673
-
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
-
Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043):a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–712.
-
(2014)
Lancet Oncol
, vol.15
, Issue.7
, pp. 700-712
-
-
Kwon, E.D.1
Drake, C.G.2
Scher, H.I.3
-
24
-
-
84929481481
-
Pembrolizumab versus ipilimumab in advanced melanoma
-
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
-
(2015)
N Engl J Med
, vol.372
, Issue.26
, pp. 2521-2532
-
-
Robert, C.1
Schachter, J.2
Long, G.V.3
-
25
-
-
84923166043
-
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma
-
Gibney GT, Kudchadkar RR, DeConti RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21(4):712–720.
-
(2015)
Clin Cancer Res
, vol.21
, Issue.4
, pp. 712-720
-
-
Gibney, G.T.1
Kudchadkar, R.R.2
DeConti, R.C.3
-
26
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133.
-
(2013)
N Engl J Med
, vol.369
, Issue.2
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
-
27
-
-
85016509105
-
Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab
-
Weber J, Gibney G, Kudchadkar R, et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res. 2016;4(4):345–353.
-
(2016)
Cancer Immunol Res
, vol.4
, Issue.4
, pp. 345-353
-
-
Weber, J.1
Gibney, G.2
Kudchadkar, R.3
-
28
-
-
84874605864
-
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
-
Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616–622.
-
(2013)
J Clin Oncol
, vol.31
, Issue.5
, pp. 616-622
-
-
Ribas, A.1
Kefford, R.2
Marshall, M.A.3
-
29
-
-
84938205998
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
-
Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002):a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–918.
-
(2015)
Lancet Oncol
, vol.16
, Issue.8
, pp. 908-918
-
-
Ribas, A.1
Puzanov, I.2
Dummer, R.3
-
30
-
-
84950117835
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
-
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial. Lancet (London, England). 2016;387(10027):1540–1550.
-
(2016)
Lancet (London, England)
, vol.387
, Issue.10027
, pp. 1540-1550
-
-
Herbst, R.S.1
Baas, P.2
Kim, D.W.3
-
31
-
-
84964341647
-
Association of pembrolizumab with tumor response and survival among patients with advanced melanoma
-
Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. Jama. 2016;315(15):1600–1609.
-
(2016)
Jama
, vol.315
, Issue.15
, pp. 1600-1609
-
-
Ribas, A.1
Hamid, O.2
Daud, A.3
-
32
-
-
84879759020
-
Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma
-
Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N Engl J Med. 2013;369(2):134–144.
-
(2013)
N Engl J Med
, vol.369
, Issue.2
, pp. 134-144
-
-
Hamid, O.1
Robert, C.2
Daud, A.3
-
33
-
-
84908354848
-
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
-
Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma:a randomised dose-comparison cohort of a phase 1 trial. The Lancet. 2014;384(9948):1109–1117.
-
(2014)
The Lancet
, vol.384
, Issue.9948
, pp. 1109-1117
-
-
Robert, C.1
Ribas, A.2
Wolchok, J.D.3
-
34
-
-
84971619894
-
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
-
Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases:early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–983.
-
(2016)
Lancet Oncol
, vol.17
, Issue.7
, pp. 976-983
-
-
Goldberg, S.B.1
Gettinger, S.N.2
Mahajan, A.3
-
35
-
-
84969988424
-
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
-
Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012):an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965.
-
(2016)
Lancet Oncol
, vol.17
, Issue.7
, pp. 956-965
-
-
Seiwert, T.Y.1
Burtness, B.2
Mehra, R.3
-
36
-
-
84904024273
-
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
-
Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074.
-
(2014)
Clin Cancer Res
, vol.20
, Issue.19
, pp. 5064-5074
-
-
Taube, J.M.1
Klein, A.2
Brahmer, J.R.3
-
37
-
-
84944937210
-
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
-
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
-
(2015)
N Engl J Med
, vol.373
, Issue.17
, pp. 1627-1639
-
-
Borghaei, H.1
Paz-Ares, L.2
Horn, L.3
-
38
-
-
84951126341
-
Safety and antitumor activity of anti–pd-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer
-
Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti–pd-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–4022.
-
(2015)
J Clin Oncol
, vol.33
, Issue.34
, pp. 4015-4022
-
-
Hamanishi, J.1
Mandai, M.2
Ikeda, T.3
-
39
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England J Med. 2015;373(1):23–34.
-
(2015)
New England J Med
, vol.373
, Issue.1
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
-
41
-
-
84929481482
-
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
-
Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017.
-
(2015)
N Engl J Med
, vol.372
, Issue.21
, pp. 2006-2017
-
-
Postow, M.A.1
Chesney, J.2
Pavlick, A.C.3
-
42
-
-
84931083080
-
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
-
Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384.
-
(2015)
Lancet Oncol
, vol.16
, Issue.4
, pp. 375-384
-
-
Weber, J.S.1
D’Angelo, S.P.2
Minor, D.3
-
43
-
-
84929361060
-
Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab
-
McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013–2020.
-
(2015)
J Clin Oncol
, vol.33
, Issue.18
, pp. 2013-2020
-
-
McDermott, D.F.1
Drake, C.G.2
Sznol, M.3
-
44
-
-
84924901863
-
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
-
Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–265.
-
(2015)
Lancet Oncol
, vol.16
, Issue.3
, pp. 257-265
-
-
Rizvi, N.A.1
Mazieres, J.2
Planchard, D.3
-
45
-
-
84925222119
-
Nivolumab in previously untreated melanoma without BRAF mutation
-
Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.
-
(2015)
N Engl J Med
, vol.372
, Issue.4
, pp. 320-330
-
-
Robert, C.1
Long, G.V.2
Brady, B.3
-
46
-
-
84898973055
-
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
-
Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030.
-
(2014)
J Clin Oncol
, vol.32
, Issue.10
, pp. 1020-1030
-
-
Topalian, S.L.1
Sznol, M.2
McDermott, D.F.3
-
47
-
-
84936937852
-
A phase 2 study of tremelimumab in patients with advanced uveal melanoma
-
Joshua AM, Monzon JG, Mihalcioiu C, et al. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res. 2015;25(4):342–347.
-
(2015)
Melanoma Res
, vol.25
, Issue.4
, pp. 342-347
-
-
Joshua, A.M.1
Monzon, J.G.2
Mihalcioiu, C.3
-
48
-
-
84926418972
-
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
-
Calabrò L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma:an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015;3(4):301–309.
-
(2015)
Lancet Respir Med
, vol.3
, Issue.4
, pp. 301-309
-
-
Calabrò, L.1
Morra, A.2
Fonsatti, E.3
-
49
-
-
84879141840
-
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
-
Sangro B, Gomez-Martin C, De La Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–88.
-
(2013)
J Hepatol
, vol.59
, Issue.1
, pp. 81-88
-
-
Sangro, B.1
Gomez-Martin, C.2
De La Mata, M.3
-
50
-
-
77955292303
-
Phase II study of the anti-cytotoxic t-lymphocyte–associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer
-
Chung KY, Gore I, Fong L, et al. Phase II study of the anti-cytotoxic t-lymphocyte–associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010;28(21):3485–3490.
-
(2010)
J Clin Oncol
, vol.28
, Issue.21
, pp. 3485-3490
-
-
Chung, K.Y.1
Gore, I.2
Fong, L.3
-
51
-
-
84959577118
-
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
-
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:a single-arm, multicentre, phase 2 trial. The Lancet. 2016;387(10031):1909–1920.
-
(2016)
The Lancet
, vol.387
, Issue.10031
, pp. 1909-1920
-
-
Rosenberg, J.E.1
Hoffman-Censits, J.2
Powles, T.3
-
52
-
-
84944718150
-
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
-
Yamazaki N, Kiyohara Y, Uhara H, et al. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother Pharmacol. 2015;76(5):997–1004.
-
(2015)
Cancer Chemother Pharmacol
, vol.76
, Issue.5
, pp. 997-1004
-
-
Yamazaki, N.1
Kiyohara, Y.2
Uhara, H.3
-
53
-
-
84944896352
-
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
-
Yamazaki N, Uhara H, Fukushima S, et al. Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. Cancer Chemother Pharmacol. 2015;76(5):969–975.
-
(2015)
Cancer Chemother Pharmacol
, vol.76
, Issue.5
, pp. 969-975
-
-
Yamazaki, N.1
Uhara, H.2
Fukushima, S.3
-
54
-
-
84924543977
-
Phase II decog-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma
-
Zimmer L, Vaubel J, Mohr P, et al. Phase II decog-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One. 2015;10(3):e0118564.
-
(2015)
PLoS One
, vol.10
, Issue.3
, pp. e0118564
-
-
Zimmer, L.1
Vaubel, J.2
Mohr, P.3
-
55
-
-
84908664534
-
Sargramostim plus ipilimumab vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial
-
Hodi FS, Lee S, McDermott DF, et al. Sargramostim plus ipilimumab vs ipilimumab alone for treatment of metastatic melanoma:a randomized clinical trial. JAMA. 2014;312(17):1744–1753.
-
(2014)
JAMA
, vol.312
, Issue.17
, pp. 1744-1753
-
-
Hodi, F.S.1
Lee, S.2
McDermott, D.F.3
-
56
-
-
84964313298
-
Bevacizumab plus ipilimumab in patients with metastatic melanoma
-
Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2(7):632–642.
-
(2014)
Cancer Immunol Res
, vol.2
, Issue.7
, pp. 632-642
-
-
Hodi, F.S.1
Lawrence, D.2
Lezcano, C.3
-
57
-
-
84896489380
-
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
-
Jochems C, Tucker JA, Tsang K-Y, et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients:immune correlates. Ancer Immunol Immunother. 2014;63(4):407–418.
-
(2014)
Ancer Immunol Immunother
, vol.63
, Issue.4
, pp. 407-418
-
-
Jochems, C.1
Tucker, J.A.2
Tsang, K.-Y.3
-
58
-
-
84863911486
-
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study
-
Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer:results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046–2054.
-
(2012)
J Clin Oncol
, vol.30
, Issue.17
, pp. 2046-2054
-
-
Lynch, T.J.1
Bondarenko, I.2
Luft, A.3
-
59
-
-
84871532643
-
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
-
Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer:results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75–83.
-
(2013)
Ann Oncol
, vol.24
, Issue.1
, pp. 75-83
-
-
Reck, M.1
Bondarenko, I.2
Luft, A.3
-
60
-
-
84860446616
-
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
-
Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases:an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–465.
-
(2012)
Lancet Oncol
, vol.13
, Issue.5
, pp. 459-465
-
-
Margolin, K.1
Ernstoff, M.S.2
Hamid, O.3
-
61
-
-
84860455345
-
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
-
Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer:a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501–508.
-
(2012)
Lancet Oncol
, vol.13
, Issue.5
, pp. 501-508
-
-
Madan, R.A.1
Mohebtash, M.2
Arlen, P.M.3
-
62
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526.
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
-
63
-
-
77958050577
-
Phase 2 trial of single agent ipilimumab (anti-ctla-4) for locally advanced or metastatic pancreatic adenocarcinoma
-
Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (anti-ctla-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828–833.
-
(2010)
J Immunother
, vol.33
, Issue.8
, pp. 828-833
-
-
Royal, R.E.1
Levy, C.2
Turner, K.3
-
64
-
-
84963506978
-
Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report
-
Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis:case report. Can J Ophthalmol. 2016;51(1):e4–e6.
-
(2016)
Can J Ophthalmol
, vol.51
, Issue.1
, pp. e4-e6
-
-
Basilious, A.1
Lloyd, J.C.2
-
66
-
-
84964389238
-
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
-
Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–225.
-
(2016)
Eur J Cancer
, vol.60
, pp. 210-225
-
-
Zimmer, L.1
Goldinger, S.M.2
Hofmann, L.3
-
67
-
-
84971222304
-
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
-
Hahn L, Pepple KL. Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. J Ophthalmic Inflamm Infect. 2016;6:14.
-
(2016)
J Ophthalmic Inflamm Infect
, vol.6
, pp. 14
-
-
Hahn, L.1
Pepple, K.L.2
-
68
-
-
84967153386
-
Intraocular inflammation associated with new therapies for cutaneous melanoma–case series and review
-
Fierz FC, Meier F, Chaloupka K, et al. Intraocular inflammation associated with new therapies for cutaneous melanoma–case series and review. Klin Monatsbl Augenheilkd. 2016;233(04):540–544.
-
(2016)
Klin Monatsbl Augenheilkd
, vol.233
, Issue.4
, pp. 540-544
-
-
Fierz, F.C.1
Meier, F.2
Chaloupka, K.3
-
69
-
-
84995743532
-
A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma
-
Hanna KS. A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma. Pharmacotherapy. 2016;36:e183-e188.
-
(2016)
Pharmacotherapy
, vol.36
, pp. e183-e188
-
-
Hanna, K.S.1
-
70
-
-
85015859208
-
Pembrolizumab administration associated with posterior uveitis
-
Aaberg MT, Aaberg TM, Jr. Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep. 2016. [Epub ahead of print].
-
(2016)
Retin Cases Brief Rep
-
-
Aaberg, M.T.1
Aaberg, T.M.2
-
71
-
-
84988428989
-
Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient
-
Arai T, Harada K, Usui Y, et al. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol. 2016 doi:10.1111/1346-8138.13612. [Epub ahead of print]
-
(2016)
J Dermatol
-
-
Arai, T.1
Harada, K.2
Usui, Y.3
-
72
-
-
85043524023
-
Bilateral anterior uveitis associated with nivolumab therapy
-
Karlin J, Gentzler R, Golen J. Bilateral anterior uveitis associated with nivolumab therapy. Ocul Immunol Inflamm. 2016;1–3. [Epub ahead of print].
-
(2016)
Ocul Immunol Inflamm
, pp. 1-3
-
-
Karlin, J.1
Gentzler, R.2
Golen, J.3
-
73
-
-
84956836603
-
Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment
-
De Velasco G, Bermas B, Choueiri TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheum (Hoboken, NJ). 2016;68(2):556–557.
-
(2016)
Arthritis Rheum (Hoboken, NJ)
, vol.68
, Issue.2
, pp. 556-557
-
-
De Velasco, G.1
Bermas, B.2
Choueiri, T.K.3
-
74
-
-
84922976477
-
New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient
-
Miserocchi E, Cimminiello C, Mazzola M, et al. New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol. 2015;50(1):e2–4.
-
(2015)
Can J Ophthalmol
, vol.50
, Issue.1
, pp. e2-e4
-
-
Miserocchi, E.1
Cimminiello, C.2
Mazzola, M.3
-
75
-
-
84906276850
-
Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash
-
Nallapaneni NN, Mourya R, Bhatt VR, et al. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J Natl Compr Canc Netw. 2014;12(8):1077–1081.
-
(2014)
J Natl Compr Canc Netw
, vol.12
, Issue.8
, pp. 1077-1081
-
-
Nallapaneni, N.N.1
Mourya, R.2
Bhatt, V.R.3
-
76
-
-
84997235698
-
Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab
-
Roberts P, Fishman GA, Joshi K, et al. Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab. JAMA Ophthalmol. 2016;134(10):1184–1188.
-
(2016)
JAMA Ophthalmol
, vol.134
, Issue.10
, pp. 1184-1188
-
-
Roberts, P.1
Fishman, G.A.2
Joshi, K.3
-
77
-
-
85015891770
-
Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients
-
Nguyen BH, Kuo J, Budiman A, et al. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res. 2016. [Epub ahead of print].
-
(2016)
Melanoma Res
-
-
Nguyen, B.H.1
Kuo, J.2
Budiman, A.3
-
78
-
-
84940182635
-
Ipilimumab-induced ocular and orbital inflammation–a case series and review of the literature
-
Papavasileiou E, Prasad S, Freitag SK, et al. Ipilimumab-induced ocular and orbital inflammation–a case series and review of the literature. Ocul Immunol Inflamm. 2016;24(2):140–146.
-
(2016)
Ocul Immunol Inflamm
, vol.24
, Issue.2
, pp. 140-146
-
-
Papavasileiou, E.1
Prasad, S.2
Freitag, S.K.3
-
79
-
-
84864052441
-
Management of immune-related adverse events and kinetics of response with ipilimumab
-
Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–2697.
-
(2012)
J Clin Oncol
, vol.30
, Issue.21
, pp. 2691-2697
-
-
Weber, J.S.1
Kähler, K.C.2
Hauschild, A.3
-
80
-
-
84959082340
-
Cyclosporine for dry eye associated with nivolumab: a case progressing to corneal perforation
-
Nguyen AT, Elia M, Materin MA, et al. Cyclosporine for dry eye associated with nivolumab:a case progressing to corneal perforation. Cornea. 2016;35(3):399–401.
-
(2016)
Cornea
, vol.35
, Issue.3
, pp. 399-401
-
-
Nguyen, A.T.1
Elia, M.2
Materin, M.A.3
-
81
-
-
84964703568
-
Ocular and orbital side-effects of checkpoint inhibitors: a review article
-
Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors:a review article. Curr Opin Oncol. 2016;28(4):288–294.
-
(2016)
Curr Opin Oncol
, vol.28
, Issue.4
, pp. 288-294
-
-
Antoun, J.1
Titah, C.2
Cochereau, I.3
-
82
-
-
84974678928
-
Immune check point inhibitors combination in melanoma: worth the toxicity?
-
Orloff M, Weight R, Valsecchi ME, et al. Immune check point inhibitors combination in melanoma:worth the toxicity? Rev Recent Clin Trials. 2016;11(2):81–86.
-
(2016)
Rev Recent Clin Trials
, vol.11
, Issue.2
, pp. 81-86
-
-
Orloff, M.1
Weight, R.2
Valsecchi, M.E.3
-
83
-
-
84988672464
-
Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy?
-
Diem S, Keller F, Ruesch R, et al. Pembrolizumab-triggered uveitis:an additional surrogate marker for responders in melanoma immunotherapy? J Immunother. 2016;39(9):379–382.
-
(2016)
J Immunother
, vol.39
, Issue.9
, pp. 379-382
-
-
Diem, S.1
Keller, F.2
Ruesch, R.3
|